"Bear....Is this why SGLT2 inhibitors synergized so well with ABL in the BOM trial ?"

The cardioprotective effects of SGLT2 inhibitors have been known since empagliflozin in EMPA-REG OUTCOMES was first reported in late 2015. This is not new. However, the reason for synergy of apabetalone with SGLT2 inhibitors (and possibly DPP4 inhibitors and GLP1-R agonists) has yet to be mechanistically explained. 

BDAZ